DK3254110T3 - Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1) - Google Patents
Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1) Download PDFInfo
- Publication number
- DK3254110T3 DK3254110T3 DK16702150.0T DK16702150T DK3254110T3 DK 3254110 T3 DK3254110 T3 DK 3254110T3 DK 16702150 T DK16702150 T DK 16702150T DK 3254110 T3 DK3254110 T3 DK 3254110T3
- Authority
- DK
- Denmark
- Prior art keywords
- assess
- expression
- programmed death
- death ligand
- histochemical test
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562111352P | 2015-02-03 | 2015-02-03 | |
PCT/EP2016/052107 WO2016124558A1 (en) | 2015-02-03 | 2016-02-02 | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3254110T3 true DK3254110T3 (da) | 2020-05-18 |
Family
ID=55272501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16702150.0T DK3254110T3 (da) | 2015-02-03 | 2016-02-02 | Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1) |
Country Status (5)
Country | Link |
---|---|
US (1) | US10620211B2 (da) |
EP (1) | EP3254110B1 (da) |
DK (1) | DK3254110T3 (da) |
ES (1) | ES2791950T3 (da) |
WO (1) | WO2016124558A1 (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017019559B1 (pt) | 2015-03-13 | 2020-08-04 | Cytomx Therapeutics, Inc | Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes |
TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
CA3037230A1 (en) * | 2016-09-20 | 2018-03-29 | Merck Patent Gmbh | Diagnostic anti-pd-l1 antibody and use thereof |
KR20240011262A (ko) | 2017-02-21 | 2024-01-25 | 리제너론 파아마슈티컬스, 인크. | 폐암의 치료를 위한 항-pd-1 항체 |
KR20200016899A (ko) | 2017-06-01 | 2020-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항-pdl1 항체, 및 이의 이용 방법 |
CN107266572A (zh) * | 2017-07-13 | 2017-10-20 | 无锡傲锐东源生物科技有限公司 | 抗pd‑l1蛋白单克隆抗体及其用途 |
CN108864284A (zh) * | 2018-04-02 | 2018-11-23 | 南京基诺米医疗科技有限公司 | 兔抗人pd-l1蛋白单克隆抗体制备及其免疫组化用途 |
KR102567972B1 (ko) | 2018-06-04 | 2023-08-17 | 삼성전자주식회사 | 유기 이미지 센서 |
BR112021021713A2 (pt) | 2019-05-13 | 2022-04-19 | Regeneron Pharma | Método de tratamento de câncer ou inibição do crescimento de um tumor |
WO2021242728A1 (en) | 2020-05-26 | 2021-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab |
IL300328A (en) | 2020-08-26 | 2023-04-01 | Regeneron Pharma | Methods for treating cancer by administering a PD-1 inhibitor |
WO2024076926A1 (en) | 2022-10-03 | 2024-04-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1564604A (en) | 1925-06-12 | 1925-12-08 | Chas S Hodges | Water wheel |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
US5922855A (en) | 1993-12-17 | 1999-07-13 | Oregon Health Sciences University | Mammalian DNA mismatch repair genes MLH1 and PMS1 |
ATE350472T1 (de) | 1997-10-21 | 2007-01-15 | Univ Glasgow | Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen |
EP1210424B1 (en) | 1999-08-23 | 2007-02-07 | Dana-Farber Cancer Institute, Inc. | Novel b7-4 molecules and uses therefor |
US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
WO2001039722A2 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US6670113B2 (en) | 2001-03-30 | 2003-12-30 | Nanoprobes | Enzymatic deposition and alteration of metals |
CA2453450A1 (en) | 2001-07-20 | 2003-11-06 | Quantum Dot Corporation | Luminescent nanoparticles and methods for their preparation |
DK1636586T3 (da) | 2003-06-24 | 2009-11-23 | Ventana Med Syst Inc | Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser |
AU2012211347B9 (en) | 2004-07-20 | 2015-06-18 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
EP3428191A1 (en) | 2004-10-06 | 2019-01-16 | Mayo Foundation for Medical Education and Research | B7-h1 and pd-1 in treatment of renal cell carcinoma |
US7895540B2 (en) | 2006-08-02 | 2011-02-22 | Georgia Tech Research Corporation | Multilayer finite difference methods for electrical modeling of packages and printed circuit boards |
DK2342226T3 (da) | 2008-09-26 | 2016-09-26 | Dana Farber Cancer Inst Inc | Humane anti-pd-1-, pd-l1- og pd-l2-antistoffer og anvendelser deraf |
CN108997498A (zh) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
EP3375791A1 (en) | 2009-09-30 | 2018-09-19 | Memorial Sloan Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
JP2013531801A (ja) | 2010-07-02 | 2013-08-08 | ヴェンタナ メディカル システムズ, インク. | 標的検出のためのハプテンコンジュゲート |
CN102250911A (zh) | 2011-05-31 | 2011-11-23 | 苏州大学 | 一种可溶性b7-h1定量检测试剂盒 |
KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-pd-l1 항체 및 그의 용도 |
WO2013172926A1 (en) | 2012-05-14 | 2013-11-21 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
CN104470949A (zh) * | 2012-05-15 | 2015-03-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
CN111499755A (zh) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
WO2014165082A2 (en) * | 2013-03-13 | 2014-10-09 | Medimmune, Llc | Antibodies and methods of detection |
AR095363A1 (es) * | 2013-03-15 | 2015-10-14 | Genentech Inc | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 |
WO2014165422A1 (en) * | 2013-04-02 | 2014-10-09 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
US20160215052A1 (en) | 2013-07-24 | 2016-07-28 | Dana-Farber Cancer Institute, Inc. | Anti-galectin-1 (gal1) monoclonal antibodies and fragments thereof for neutralizing gal1 |
GB201316024D0 (en) | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for lung cancer |
GB201316027D0 (en) | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for oesophageal cancer |
WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
NZ718821A (en) | 2013-09-11 | 2022-07-01 | Medimmune Ltd | Anti-b7-h1 antibodies for treating tumors |
AU2014339900B2 (en) | 2013-10-25 | 2019-10-24 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
US10241115B2 (en) | 2013-12-10 | 2019-03-26 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue |
AU2015220750B2 (en) | 2014-02-24 | 2020-04-16 | Ventana Medical Systems, Inc. | Quinone methide analog signal amplification |
CA2947932C (en) * | 2014-05-29 | 2021-03-30 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
CA2947687C (en) * | 2014-05-30 | 2021-07-06 | Ventana Medical Systems, Inc. | Multiplex assay for improved scoring of tumor tissues stained for pd-l1 |
JP6800152B2 (ja) * | 2014-11-10 | 2020-12-16 | ベンタナ メディカル システムズ, インコーポレイテッド | 組織学画像中の核の分類 |
-
2016
- 2016-02-02 DK DK16702150.0T patent/DK3254110T3/da active
- 2016-02-02 WO PCT/EP2016/052107 patent/WO2016124558A1/en active Application Filing
- 2016-02-02 EP EP16702150.0A patent/EP3254110B1/en active Active
- 2016-02-02 ES ES16702150T patent/ES2791950T3/es active Active
-
2017
- 2017-07-28 US US15/663,640 patent/US10620211B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2791950T3 (es) | 2020-11-06 |
EP3254110B1 (en) | 2020-03-18 |
WO2016124558A1 (en) | 2016-08-11 |
EP3254110A1 (en) | 2017-12-13 |
US10620211B2 (en) | 2020-04-14 |
US20170343556A1 (en) | 2017-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3254110T3 (da) | Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1) | |
HK1256303A1 (zh) | 程序性細胞死亡1配體1 (pd-l1)的irna組合物及其使用方法 | |
DK3538864T3 (da) | Mikrotom | |
DK3359095T3 (da) | Automatiseret hånd | |
DK3140653T3 (da) | Direkte immunhistokemianalyse | |
DK3757214T3 (da) | Sammensætninger til modulering af sod-1-ekspression | |
DK3386548T3 (da) | Inositol-derivater til anvendelse i patologisk krystallisering | |
DK3236749T3 (da) | Flydende tribenuron-holdige herbicidsammensætninger | |
FI20155101A (fi) | Nanofibrillaarinen selluloosakoostumus | |
DK3384274T3 (da) | Fremgangsmåder til prøvekarakterisering | |
DK3119888T3 (da) | Sammensætninger til at modulere ataxin-2-ekspression | |
DK3613447T3 (da) | Humane pancreas-scaffolds | |
BR112017000270A2 (pt) | método para vedar substâncias e método de detecção de molécula alvo | |
DK3120129T3 (da) | Holder til kerneprøver | |
DK3364189T3 (da) | Immunkromatografisk teststykke | |
DK3258174T3 (da) | Ovn | |
DK3445157T3 (da) | Udtrækkelig plantebakkeenhed | |
DK3298133T3 (da) | Acetatforbrugende gærcelle | |
DK3397734T3 (da) | Brændstofsammensætning | |
DK3305977T3 (da) | Automatisk stoftilfører | |
DK3220057T3 (da) | Flammesimuleringsenhed | |
DK3513192T3 (da) | Celledødsbiomarkør | |
DK3397933T3 (da) | Testprobe til et filter | |
DK3371050T3 (da) | Vingeløst luftfartøj | |
DK3357520T3 (da) | Viskoelastisk sammensætning |